Evidence map›Paper›PMID 35176252›Full record

ArticleHuman pathology2022

Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis.

Samuel Ruder, Yan Gao, Yi Ding, Ping Bu, Brian Miles, Angelo De Marzo, Thomas Wheeler, Jesse K McKenney, Heidi Auman, Ladan Fazli and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Samuel RuderDepartment of Pathology and Laboratory Medicine, University of Texas Health Sciences Center Medical School, Houston, TX 77030, USA.
Yan GaoDepartment of Pathology and Laboratory Medicine, University of Texas Health Sciences Center Medical School, Houston, TX 77030, USA.
Yi DingDepartment of Pathology and Laboratory Medicine, University of Texas Health Sciences Center Medical School, Houston, TX 77030, USA.
Ping BuDepartment of Pathology and Laboratory Medicine, University of Texas Health Sciences Center Medical School, Houston, TX 77030, USA.
Brian MilesDepartment of Urology, The Methodist Hospital, Houston, TX, 77030, USA.
Angelo De MarzoDepartments of Pathology, Epidemiology and Urology, Johns Hopkins Hospital School of Medicine, Baltimore, MD, 21287, USA.
Thomas WheelerDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
Jesse K McKenneyDepartment of Urology, Cleveland Clinic Foundation, Mail Code L25 Cleveland, OH, 44195, USA.
Heidi AumanCanary Foundation, Palo Alto, CA, 94304, USA.
Ladan FazliVancouver Prostate Centre, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada.
Jeff SimkoDepartment of Pathology, University of California San Francisco, San Francisco, CA, 94143-0511, USA.
Antonio Hurtado-CollVancouver Prostate Centre, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada.
Dean A TroyerDepartment of Pathology, Eastern Virginia Medical School, Norfolk, VA, 23501-1980, USA.
Peter R CarrollDepartment of Urology, University of California San Francisco, San Francisco, CA, 94143-0330, USA.
Martin GleaveVancouver Prostate Centre, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada.
Elizabeth PlatzDepartments of Pathology, Epidemiology and Urology, Johns Hopkins Hospital School of Medicine, Baltimore, MD, 21287, USA.
Bruce TrockDepartments of Pathology, Epidemiology and Urology, Johns Hopkins Hospital School of Medicine, Baltimore, MD, 21287, USA.
Misop HanDepartments of Pathology, Epidemiology and Urology, Johns Hopkins Hospital School of Medicine, Baltimore, MD, 21287, USA.
Mohammad SayeeduddinDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
Lawrence D TrueDepartment of Urology, University of Washington, Surgery Pavilion, Seattle, WA, 98195, USA.
David RowleyDepartment of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, 77030, USA.
Daniel W LinDepartment of Urology, University of Washington, Surgery Pavilion, Seattle, WA, 98195, USA.
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.
Ian M ThompsonDepartment of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, 78229-3900, USA.
Ziding FengBiostatistics Department - Unit 1411, The University of Texas MD Anderson Cancer Center, Houston, TX, 77230-1402, USA.
Wei WeiBiostatistics Department - Unit 1411, The University of Texas MD Anderson Cancer Center, Houston, TX, 77230-1402, USA.
James D BrooksDepartment of Urology, Stanford University, Palo Alto, CA, 94304, USA.
Michael IttmannDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
MinJae LeeBiostatistics/Epidemiology/Research Design (BERD) Core, Department of Internal Medicine, University of Texas Health Sciences Center Medical School, Houston, TX, 77030, USA.
Gustavo AyalaDepartment of Pathology and Laboratory Medicine, University of Texas Health Sciences Center Medical School, Houston, TX 77030, USA. Electronic address: Gustavo.E.Ayala@uth.tmc.edu.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8M
Predicting Prostate Cancer AggressivenessU01CA151924 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ANDERSON, ALEXANDER ROBERTSON ALLAN, AYALA, GUSTAVO ENRIQUE · 2011 to 2015
$2.8M
Resistance to Cancer Therapeutics Through Microenvironment Damage Responses.R01CA165573 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NELSON, PETER S · 2012 to 2016
$1.8M
Non Invasive Biomarkers for Diagnosing Clinically Significant Prostate CancerR01CA181605 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NELSON, PETER S · 2014 to 2018
$1.8M
Comprehensive Tumor Microenvironment Based Prediction Models in Prostate CancerR01CA140734 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI AYALA, GUSTAVO ENRIQUE · 2011 to 2015
$1.5M
InForm image segmentation image analysis software and Vectra automation systemS10RR026442 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI AYALA, GUSTAVO ENRIQUE · 2010 to 2010
$354k
NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA058236NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA140734NCI NIH HHS R01 CA165573NCI NIH HHS R01 CA181605NCI NIH HHS U01 CA151924NCI NIH HHS U01 CA196390NCRR NIH HHS S10 RR026442
6 · The paper itself

Abstract

To develop and validate a new tissue-based biomarker that improves prediction of outcomes in localized prostate cancer by quantifying the host response to tumor. We use digital image analysis and machine learning to develop a biomarker of the prostate stroma called quantitative reactive stroma (qRS). qRS is a measure of percentage tumor area with a distinct, reactive stromal architecture. Kaplan Meier analysis was used to determine survival in a large retrospective cohort of radical prostatectomy samples. qRS was validated in two additional, distinct cohorts that include international cases and tissue from both radical prostatectomy and biopsy specimens. In the developmental cohort (Baylor College of Medicine, n = 482), patients whose tumor had qRS > 34% had increased risk of prostate cancer-specific death (HR 2.94; p = 0.039). This result was replicated in two validation cohorts, where patients with qRS > 34% had increased risk of prostate cancer-specific death (MEDVAMC; n = 332; HR 2.64; p = 0.02) and also biochemical recurrence (Canary; n = 988; HR 1.51; p = 0.001). By multivariate analysis, these associations were shown to hold independent predictive value when compared to currently used clinicopathologic factors including Gleason score and PSA. qRS is a new, validated biomarker that predicts prostate cancer death and biochemical recurrence across three distinct cohorts. It measures host-response rather than tumor-based characteristics, and provides information not represented by standard prognostic measurements.

Indexed as

ProstateProstatic NeoplasmsBiomarkers, TumorHumansMaleNeoplasm Recurrence, LocalPrognosisProstatectomyProstate-Specific AntigenRetrospective StudiesBiomarkers, TumorProstate-Specific AntigenBiomarkerCancerHost responseProstateStroma

Identifiers

PMID35176252
PMCPMC9832989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.